Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 217S · 10 late217 trades$54.77M| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 31 | Prosor MayaChief Business Officer |  LMNDLemonade, Inc.Open-market sale | SELL | $57K 1,040 sh | Sep 8, 2026 |
| 31 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER |  LTHLife Time Group Holdings, Inc.Open-market sale | SELL | $249K 5,666 sh | Sep 8, 2026 traded Sep 3, 2026 |
| 56 | De Angoitia AlfonsoDirector |  LILALiberty Latin America Ltd.Open-market purchase | BUY | $3.06M 145.5K sh | Sep 4, 2026 traded Aug 31, 2026 |
| 52 | Lacerte Rene A.Director, CEO |  BILLBILL Holdings, Inc.Open-market sale | SELL | $4.90M 100.9K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 50 | Spetzler David BaxleyPresident |  CAICaris Life Sciences, Inc.Open-market sale | SELL | $9.73M 393.1K sh | Sep 4, 2026 traded Sep 3, 2026 |
| 50 | Steiner Jason RobertSEE REMARKS |  PFLEXPIMCO Flexible Credit Income FundOpen-market purchase | BUY | $1.01M 148.8K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 48 | Lacerte Rene A.Director, CEO | BILLBILL Holdings, Inc. Open-market sale | SELL | $1.94M 40.4K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 48 | Lacerte Rene A.Director, CEO | BILLBILL Holdings, Inc. Open-market sale | SELL | $1.31M 27.0K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 46 | Coloma Jason VDirector, Chief Executive Officer | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $293K 11.3K sh | Sep 4, 2026 traded Sep 3, 2026 |
| 46 | Spetzler David BaxleyPresident | CAICaris Life Sciences, Inc. Open-market sale | SELL | $2.15M 84.9K sh | Sep 4, 2026 traded Sep 3, 2026 |
| 46 | De Angoitia AlfonsoDirector | LILALiberty Latin America Ltd. Open-market purchase | BUY | $6.56M 313.1K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 46 | Coloma Jason VDirector, Chief Executive Officer | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $260K 9,852 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 44 | Lacerte Rene A.Director, CEO | BILLBILL Holdings, Inc. Open-market sale | SELL | $1.18M 24.4K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 44 | Tang StanleyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $3.52M 15.5K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 43 | Courtney PhillipsGC and Corp. Secretary | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $52K 1,990 sh | Sep 4, 2026 traded Sep 3, 2026 |
| 42 | Ware J. AnthonyDirector |  TRAXFirst Tracks Biotherapeutics, Inc.Open-market sale | SELL | $1.76M 39.3K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 41 | Lacerte Rene A.Director, CEO | BILLBILL Holdings, Inc. Open-market sale | SELL | $511K 10.6K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 41 | De Angoitia AlfonsoDirector | LILALiberty Latin America Ltd. Open-market purchase | BUY | $363K 17.6K sh | Sep 4, 2026 traded Sep 1, 2026 |
| 41 | Lacerte Rene A.Director, CEO | BILLBILL Holdings, Inc. Open-market sale | SELL | $565K 11.8K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 40 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $118K 4,481 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 40 | Tang StanleyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $1.87M 8,277 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 40 | Simon JoshDirector, Chief Executive Officer |  FNKOFunko, Inc.Open-market sale | SELL | $786K 136.3K sh | Sep 4, 2026 traded Sep 3, 2026 |
| 40 | Courtney PhillipsGC and Corp. Secretary | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $46K 1,738 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 40 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $133K 5,130 sh | Sep 4, 2026 traded Sep 3, 2026 |
| 39 | Turner Matthew BakerPRES., PATIENT AFFORDABILITY |  PAYSPaysign, Inc.Open-market sale | SELL | $63K 15.1K sh | Sep 4, 2026 traded Feb 3, 2026 |
| 39 | Landesberg StuartDirector |  GROVGrove Collaborative Holdings, Inc.Open-market purchase | BUY | $5,542 5,384 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 39 | Cunningham Bradley KramerChief Technology Officer | PAYSPaysign, Inc. Open-market sale | SELL | $73K 10.0K sh | Sep 4, 2026 traded May 29, 2026 |
| 38 | Shauli AviChief Technology Officer |  RSKDRISKIFIED LTD.Open-market sale | SELL | $193K 30.0K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 38 | Notman TaliCHIEF REVENUE OFFICER |  FROGJFrog LtdOpen-market sale | SELL | $1.73M 19.2K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 38 | Pollitzer AdamDirector, Chief Executive Officer |  NMIHNMI Holdings, Inc.Open-market sale | SELL | $7.75M 172.7K sh | Sep 4, 2026 traded Sep 4, 2026 |
| 36 | Courtney PhillipsGC and Corp. Secretary | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $6,590 243 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 36 | Marquina JavierDirector |  LPALogistic Properties of the AmericasOpen-market sale | SELL | $5,562 1,800 sh | Sep 4, 2026 traded Sep 1, 2026 |
| 36 | Spice Adam C.Chief Financial Officer | RKLBRocket Lab Corp Open-market sale · 10b5-1 plan | SELL | $4.59M 72.9K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 36 | Spice Adam C.Chief Financial Officer | RKLBRocket Lab Corp Open-market sale · 10b5-1 plan | SELL | $4.19M 67.3K sh | Sep 4, 2026 traded Sep 2, 2026 |
| 36 | Dandekar AtulCSBO | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $83K 3,207 sh | Sep 4, 2026 traded Sep 3, 2026 |
| 36 | Dandekar AtulCSBO | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $74K 2,800 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 36 | Simon JoshDirector, Chief Executive Officer | FNKOFunko, Inc. Open-market sale | SELL | $267K 45.5K sh | Sep 4, 2026 traded Sep 3, 2026 |
| 36 | Coloma Jason VDirector, Chief Executive Officer | MAZEMaze Therapeutics, Inc. Open-market sale | SELL | $37K 1,375 sh | Sep 4, 2026 traded Sep 2, 2026 |
| 35 | Lantheus Alpha Therapy, LLC10% Owner |  CATXPerspective Therapeutics, Inc.Open-market sale | SELL | $246K 78.1K sh | Sep 4, 2026 traded Aug 31, 2026 |
| 35 | Spetzler David BaxleyPresident | CAICaris Life Sciences, Inc. Open-market sale | SELL | $2.95M 119.2K sh | Sep 4, 2026 traded Sep 4, 2026 |
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
FERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
IBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
ARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
BBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K
BCYCBICYCLE THERAPEUTICS PLCOct 2 – Oct 56 insiders$63K